Immutep Post Mautre Overall Survival Data In First-Line NSCLC; Updates On TACTI-004 Analysis

Source and reference

source on Google Add Now Immutep Limited ( IMMP ), a biotechnology company developing novel immunotherapies announced encouraging results from the investigator-initiated INSIGHT-003 Phase I trial in first-line non-squamous non-small cell lung cancer. The study evaluated eftilagimod alfa in combination with Merck's KEYTRUDA and chemotherapy. About the Drug Eftilagimod alfa (efti) is a novel immunotherapy that activates antigen-presenting cells via the MHC Class II pathway, engaging both adaptive and innate immunity. It is under evaluation in multiple solid tumors, including NSCLC, head and neck cancer, soft tissue sarcoma, and breast cancer, and has received FDA Fast Track designation in first line NSCLC and HNSCC. Indication Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for around 85% of cases. Patients with advanced, non-squamous NSCLC often...